The U.S. stock market has experienced a slight downturn, following a period of gains for the S&P 500, as investors digest recent economic developments and corporate earnings. In this context, penny stocks continue to capture attention as they represent smaller or newer companies that can offer unique investment opportunities. While the term might seem outdated, these stocks still hold potential for growth when backed by strong financials and solid fundamentals.
Top 10 Penny Stocks In The United States
| Name | Share Price | Market Cap | Rewards & Risks |
| Safe Bulkers (NYSE:SB) | $3.71 | $393.17M | ✅ 4 ⚠️ 3 View Analysis > |
| Tuya (NYSE:TUYA) | $2.64 | $1.64B | ✅ 3 ⚠️ 3 View Analysis > |
| Perfect (NYSE:PERF) | $1.78 | $181.29M | ✅ 3 ⚠️ 0 View Analysis > |
| Flexible Solutions International (NYSEAM:FSI) | $4.25 | $55.65M | ✅ 1 ⚠️ 2 View Analysis > |
| Imperial Petroleum (NasdaqCM:IMPP) | $2.50 | $86.38M | ✅ 3 ⚠️ 2 View Analysis > |
| Table Trac (OTCPK:TBTC) | $4.50 | $21.82M | ✅ 2 ⚠️ 2 View Analysis > |
| BAB (OTCPK:BABB) | $0.8495 | $5.75M | ✅ 2 ⚠️ 3 View Analysis > |
| Lifetime Brands (NasdaqGS:LCUT) | $3.14 | $73.52M | ✅ 3 ⚠️ 2 View Analysis > |
| New Horizon Aircraft (NasdaqCM:HOVR) | $0.69 | $21.41M | ✅ 3 ⚠️ 5 View Analysis > |
| CBAK Energy Technology (NasdaqCM:CBAT) | $0.805 | $78.43M | ✅ 4 ⚠️ 1 View Analysis > |
Click here to see the full list of 720 stocks from our US Penny Stocks screener.
Let's explore several standout options from the results in the screener.
Black Diamond Therapeutics (NasdaqGS:BDTX)
Simply Wall St Financial Health Rating: ★★★★★★
Overview: Black Diamond Therapeutics, Inc. is a clinical-stage oncology company dedicated to discovering and developing MasterKey therapies for genetically defined tumors, with a market cap of $110.88 million.
Operations: Black Diamond Therapeutics, Inc. currently does not report any revenue segments.
Market Cap: $110.88M
Black Diamond Therapeutics has recently transitioned to profitability, reporting a net income of US$56.54 million for Q1 2025, a significant improvement from the previous year's loss. The company is debt-free with strong short-term assets of US$155.7 million exceeding liabilities and has secured a strategic licensing agreement with Servier for BDTX-4933, potentially yielding up to US$710 million in milestone payments. Despite its low return on equity at 3.6%, analysts expect substantial stock price growth, though earnings are forecasted to decline by 33.1% annually over the next three years due to its pre-revenue status in oncology therapies development.
- Dive into the specifics of Black Diamond Therapeutics here with our thorough balance sheet health report.
- Gain insights into Black Diamond Therapeutics' outlook and expected performance with our report on the company's earnings estimates.
Caribou Biosciences (NasdaqGS:CRBU)
Simply Wall St Financial Health Rating: ★★★★★★
Overview: Caribou Biosciences, Inc. is a clinical-stage biopharmaceutical company focused on developing genome-edited allogeneic cell therapies for hematologic malignancies and autoimmune diseases, with a market cap of $87.28 million.
Operations: Caribou Biosciences generates revenue primarily from developing a pipeline of allogeneic CAR-T and CAR-NK cell therapies, amounting to $9.92 million.
Market Cap: $87.28M
Caribou Biosciences, Inc. remains unprofitable with a net loss of US$39.99 million in Q1 2025, though losses have slightly narrowed compared to the previous year. The company is debt-free and holds strong short-term assets of US$217.3 million, exceeding its liabilities significantly. Recent strategic moves include a proposed reverse stock split and pipeline prioritization to extend its cash runway into late 2027. Despite high volatility and ongoing equity offerings totaling up to US$400 million, revenue is forecasted to grow substantially at over 70% annually as it advances its clinical-stage therapies for hematologic malignancies and autoimmune diseases.
- Click to explore a detailed breakdown of our findings in Caribou Biosciences' financial health report.
- Understand Caribou Biosciences' earnings outlook by examining our growth report.
Puma Biotechnology (NasdaqGS:PBYI)
Simply Wall St Financial Health Rating: ★★★★★★
Overview: Puma Biotechnology, Inc. is a biopharmaceutical company dedicated to developing and commercializing cancer care products both in the United States and internationally, with a market cap of approximately $168.27 million.
Operations: The company generates $232.71 million in revenue from the development and commercialization of innovative cancer care products.
Market Cap: $168.27M
Puma Biotechnology, Inc. has demonstrated significant earnings growth, with a 147.6% increase over the past year and profitability achieved over the last five years. The company's financial health is supported by more cash than debt and a strong balance sheet where short-term assets exceed liabilities. Recent revenue figures indicate steady performance, with US$46.01 million reported in Q1 2025 compared to US$43.8 million a year ago, alongside net income of US$2.97 million reversing prior losses. Strategic partnerships for NERLYNX® expansion into Eastern Europe and Central Asia could further bolster its market presence in oncology treatments.
- Jump into the full analysis health report here for a deeper understanding of Puma Biotechnology.
- Examine Puma Biotechnology's earnings growth report to understand how analysts expect it to perform.
Taking Advantage
- Access the full spectrum of 720 US Penny Stocks by clicking on this link.
- Interested In Other Possibilities? This technology could replace computers: discover the 22 stocks are working to make quantum computing a reality.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Valuation is complex, but we're here to simplify it.
Discover if Puma Biotechnology might be undervalued or overvalued with our detailed analysis, featuring fair value estimates, potential risks, dividends, insider trades, and its financial condition.
Access Free AnalysisHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com